<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00771693</url>
  </required_header>
  <id_info>
    <org_study_id>EudraCT number 2006-007031-27</org_study_id>
    <nct_id>NCT00771693</nct_id>
  </id_info>
  <brief_title>Effects of Insulin Treatment on Postprandial Platelet Activation in Patients With Non-insulin-dependent Diabetes Mellitus (NIDDM)</brief_title>
  <official_title>Effects of Insulin Treatment on Postprandial Platelet Activation in Patients With NIDDM: a Placebo-controlled Dose-response Study With Insulin Aspart (Novorapid®)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Karolinska Institutet</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Karolinska Institutet</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The postprandial phase in diabetic patients is characterized by a rapid increase in blood
      glucose levels, increase in platelet aggregation, LDL oxidation and over production of
      thrombin.

      The aim of the study is to determine whether meal induced platelet activation is related to
      post-prandial hyperglycemia, and can be attenuated by good postprandial glucose control with
      rapidly acting insulin in patients with T2DM.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Each patient is admitted in the fasting state, on 3 different occasions . Blood glucose
      levels are normalized using intravenous infusion of insulin aspart , to a blood glucose level
      of 6-7 mmol/l. 15 minutes after normalization ,and right before a standardized meal, the
      patient is given a subcutaneous injection of insulin aspart 0.1 U/kg, 0.2 U/kg or placebo.
      The order of injections in the cross over study is randomized and blinded to the patient and
      to the investigators. The patient eats the meal and is followed up for 90 minutes after
      completion of the meal.

      Blood tests for platelet function and other parameters are taken at 3 main points: 1. before
      glucose normalization.

      2. 15 minutes after glucose normalization, and right before the meal. 3. 90 minutes after the
      meal.

      Platelet function is evaluated by flow cytometry in whole blood (P- Selectin expression,
      Fibrinogen binding,aggregate formation: platelet- leukocyte, platelet-platelet,
      platelet-monocyte). Agonists that are used for platelet activation in flow cytometry are the
      thromboxane analogue U46619, ADP, and a collagen peptide that activates GPVI. Platelet
      adhesion is measured by the IMPACT cone and platelet analyser.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2007</start_date>
  <completion_date type="Actual">August 2010</completion_date>
  <primary_completion_date type="Actual">August 2010</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To evaluate if platelet activation following a carbohydrate rich meal is related to the post-prandial hyperglycemia, and thus can be attenuated by premeal insulin treatment in patients with T2DM.</measure>
    <time_frame>90 minutes after the meal</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Co- primary platelet response variables: U46619 stimulated platelet P- selectin activation, platelet-leukocyte aggregation, platelet-platelet aggregates and platelet-monocyte aggregates.</measure>
    <time_frame>After completion of the study in 20 patients</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To elucidate if short-term lowering of blood glucose by insulin infusion (pretreatment standardization of blood glucose) reduces platelet activity in patients with T2DM.</measure>
    <time_frame>After completion of the glucose normalization (before the meal)</time_frame>
  </secondary_outcome>
  <enrollment type="Actual">18</enrollment>
  <condition>Type 2 Diabetes Mellitus</condition>
  <condition>Postprandial Hyperglycemia</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Insulin aspart (Novorapid®)</intervention_name>
    <description>a cross-over study with subcutaneous injection of insulin aspart 0.1U/kg, 0.2u/kg or placebo, before the meal, on 3 different occasions.</description>
    <other_name>NovoRapid (Novo-Nordisk)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Type II Diabetes Mellitus.

          -  Antecubital forearm veins allowing technically good sampling for platelet studies.

          -  HbA1c 6-9 % (Mono-S method).

          -  Below 70 years

        Exclusion Criteria:

          -  History of a cardiovascular disease; Ischemic heart disease, Stroke, Peripheral
             vascular disease.

          -  Acute or chronic renal or liver disease

          -  Contraindication to insulin treatment

          -  Treatment with Glitazones, Sulphonylurea, antiplatelet drugs,

          -  Thrombocytopenia &lt;150 X109/l.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Paul Hjemdahl, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Medicine, Clinical Pharmacology Unit, Karolinska institute, Stockhom, Sweden</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of Medicine, Clinical pharmacology Unit, Karolinska University Hospital, Solna.</name>
      <address>
        <city>Stockholm</city>
        <zip>SE 171 76</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Sweden</country>
  </location_countries>
  <verification_date>November 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 10, 2008</study_first_submitted>
  <study_first_submitted_qc>October 10, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 13, 2008</study_first_posted>
  <last_update_submitted>November 4, 2010</last_update_submitted>
  <last_update_submitted_qc>November 4, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 5, 2010</last_update_posted>
  <responsible_party>
    <name_title>Prof. Paul Hjemdahl</name_title>
    <organization>Dept Medicine Solna, Clinical Pharmacology Unit, Karolinska Institute, Stockholm, Sweden</organization>
  </responsible_party>
  <keyword>NIDDM</keyword>
  <keyword>Platelet Activation</keyword>
  <keyword>Postprandial hyperglycemia</keyword>
  <keyword>insulin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
    <mesh_term>Hyperglycemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin, Globin Zinc</mesh_term>
    <mesh_term>Insulin degludec, insulin aspart drug combination</mesh_term>
    <mesh_term>Insulin</mesh_term>
    <mesh_term>Insulin Aspart</mesh_term>
    <mesh_term>Insulin, Long-Acting</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

